UK

UK Budget
#Association of the British Pharmaceutical Industry #Investment #Life sciences #UK #UK budget

UK Budget promises £70m for life sciences and lifts VAT on free medicines

In the 2026 Budget, Chancellor John Healey moved to settle a long-running VAT issue that had become a barrier to pharmaceutical companies providing free-of-charge medicines to NHS patients. Medicines supplied free of charge can provide a vital route to treatment for patients with serious conditions. Read More

#Business & Investment #News #Trending News

UK
#Clinical trial design #Clinical trials #National Institute for Health and Care Research #UK

UK clinical trial set-up times drop significantly

Efforts by the National Institute for Health and Care Research (NIHR) have led to a fall in clinical research study set-up times, new UK government figures have revealed.  Data show that the time taken to set up commercial interventional clinical trials in the UK has fallen significantly,… Read More

#News

#Association of the British Pharmaceutical Industry #MHRA #Regulatory #UK

MHRA reveals 2030 Strategy to modernise patient-centred regulation

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes.  The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More

#News #Regulatory #Trending News

#Drug discovery #Drug discovery events #Events #UK

In-person event: Drug Discovery Innovators & Investors panel covers UK regulation

The Drug Discovery Innovators & Investors (DDII) UK Conference has announced a new panel, From Rules to Runway: How UK Regulation Can Accelerate or Obstruct Drug Development,  examining how organisations can navigate the UK regulatory environment while supporting innovation and accelerating the development of new therapies. The conference takes place… Read More

#News

#Drug discovery #Drug discovery events #Events #UK

Six reasons to register for Drug Discovery Innovators & Investors UK Conference

Early bird rates for the Drug Discovery Innovators & Investors (DDII) UK Conference close on 30 September 2026. Taking place on 4 November 2026 at etc.venues Monument in London, UK, the conference brings together pharma and biotech companies, technology suppliers, academia, start-ups, spin-outs and investors for a focused day of… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Infectious diseases #Lab automation #Organoids #UK

New robotic AI lab opens in Liverpool to help fight infectious diseases  

The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool.   The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More

#News

#ABPI #Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK

ABPI paints a “hopeful” picture for the UK pharma industry

The Association of the British Pharmaceutical Industry’s (ABPI’s) 2026 flagship Competitiveness Report finds the UK has begun to reverse years of decline.  However, the Association cautions that sustained delivery of government commitments will now determine whether the recovery holds.  Since September 2025, the global pharmaceutical… Read More

#Business & Investment #News

Great British Pounds, Investment
#BioIndustry Association #Biotechnology #Investment #UK

UK biotech venture investment reaches a five-year high

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 ($2.84) billion, including a record £2.05 ($2.76) billion in venture capital, according to new figures from the BioIndustry Association (BIA).  The quarter was dominated by Isomorphic Labs’ landmark… Read More

#Business & Investment #News

Doctor showing a model of the prostate
#Johnson & Johnson #MHRA #Prostate cancer #UK

Prostate cancer therapy gets MHRA marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to a treatment for metastatic hormone-sensitive prostate cancer (mHSPC).  Akeega (niraparib and abiraterone acetate), developed by Johnson & Johnson, has been granted the authorisation as part of a combination regimen with prednisone or prednisolone and andogren deprivation therapy (ADT). … Read More

#News #Regulatory

#Clinical trial #DDII #Drug discovery #Immunology / Virology & Vaccines #Lung disease #Monoclonal antibodies #Psilocybin #UK

DDW Highlights: 14 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More

#Podcasts

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

Victoria House, London
#BioInnovation Institute #Biotech hubs #Cardiometabolic diseases #UK

BII boosts cardiometabolic innovation with new UK base

BioInnovation Institute (BII), a leading institute for life science and deep tech start-ups, has chosen its first research space outside of its headquarters in Copenhagen – Victoria House in London.  The London hub, which was developed by Pioneer Group and Oxford Properties, will serve as the flagship… Read More

#News